Exclusive Summary

• Advanced clinical status: Ranked Global Top 3 among SYK inhibitors for ITP, currently in a confirmatory Phase III trial, offering a de-risked asset profile.
• Potential Best-in-Class efficacy: Clinical data demonstrates a sustained response rate at 600 mg superior to the approved Fostamatinib and comparable to Sovleplenib.
• Long-term commercial exclusivity: Robust IP portfolio with compound patent protection theoretically extending to 2038.
• Addressed unmet need: Offers a convenient oral therapy for patients with persistent/chronic ITP who have failed first-line corticosteroid treatments.

Asset Materials

Contact Us for Full Materials